Founder, CEO & Board Member

Co-founder, Chief Scientific Officer

Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Seaport Therapeutics Presents Data Further Validating Glyph™ Platform’s Ability to Enhance Oral Bioavailability and Expand Therapeutic Reach

Seaport Therapeutics to Present at Stifel 2025 Healthcare Conference

Director, Analytical Research and Development CMC

Seaport Therapeutics is a clinical-stage therapeutics company advancing the development of novel neuropsychiatric medicines. They are hiring a Director, Analytical Research and Development, CMC to oversee the analytical method development and phase-appropriate validation of analytical methods for drug substance and drug product in pre-clinical and clinical development.

President & CEO

Chief Medical Officer

Lightspeed Venture Partners portfolio - Pheon Therapeutics(Dr. Shelley Chu - Partner)

Pheon Therapeutics Bolsters Board of Directors with Oncology R&D Expert Dr. Samuel Blackman

Cytotoxic compounds

mRNA Vaccine and Therapeutics Market Report 2025-2035: 430+ Patents Filed, Signaling Robust Growth in mRNA Intellectual Property

Director, CMC Analytical Development

Pheon Therapeutics is seeking a Director of Analytical Development to lead and build analytical strategies for ADCs in their pipeline. This role involves establishing robust analytical platforms and ensuring regulatory-ready data packages while providing scientific leadership and managing resources.

Director, Cmc Analytical Development

Director, Cmc Analytical Development in united states (1000+)

Director, Analytical Research and Development CMC

Director, CMC Analytical Development